Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
ABSTRACT Objective: Insulin Icodec is a novel basal insulin analogue designed for once-weekly administration, therefore might propitiate reduction in the frequency of injections and facilitate treatment adherence. This study aimed to determine the glycemic control and safety profile of Insulin Icod...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
2023-06-01
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000500200&lng=en&tlng=en |
| _version_ | 1797810369604878336 |
|---|---|
| author | Rodrigo Ribeiro e Silva Mateus de Miranda Gauza Maria Eduarda Schramm Guisso Júlia Opolski Nunes da Silva Suely Keiko Kohara |
| author_facet | Rodrigo Ribeiro e Silva Mateus de Miranda Gauza Maria Eduarda Schramm Guisso Júlia Opolski Nunes da Silva Suely Keiko Kohara |
| author_sort | Rodrigo Ribeiro e Silva |
| collection | DOAJ |
| description | ABSTRACT Objective: Insulin Icodec is a novel basal insulin analogue designed for once-weekly administration, therefore might propitiate reduction in the frequency of injections and facilitate treatment adherence. This study aimed to determine the glycemic control and safety profile of Insulin Icodec, compared with Glargine U100 in patients with diabetes mellitus type 2. Materials and methods: We performed a systematic review and meta-analysis of randomized controlled trials (RCT) data comparing Once-Weekly Insulin Icodec and Once-Daily Insulin Glargine U100 in patients with type 2 diabetes mellitus. PubMed, Embase, and Cochrane databases were searched for trials published up to May 14, 2022. Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Results: Three studies were included comprising 453 patients, 230 (50.77%) using Once-Weekly Insulin Icodec and 223 (49.22%) using Once-Daily Insulin Glargine U100. In the pooled data, Glycated Hemoglobin (MD -0.20% CI -0.33 to -0.07%; P=0.002) change from baseline demonstrated a significantly higher reduction in the Icodec group. Time with Glucose in Range (MD 6.60% CI 3.63 to 9.57%; P < 0.0001) and Insulin Dose Difference (MD 0.97UI CI 0.76 to 1.18UI; P < 0.0001) were higher in the Icodec group. There was no significant difference in fasting plasma glucose, body weight change, hypoglycemia or any adverse event evaluated. Conclusions: Once-Weekly Insulin Icodec was associated with a small reduction in Glycated Hemoglobin, as well as higher Time with Glucose in Range, with similar hypoglycemic adverse events, when compared with Once-Daily Insulin Glargine U100. |
| first_indexed | 2024-03-13T07:07:48Z |
| format | Article |
| id | doaj.art-9f471ce4ab3941c594ba79efe4ff363b |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-03-13T07:07:48Z |
| publishDate | 2023-06-01 |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-9f471ce4ab3941c594ba79efe4ff363b2023-06-06T07:34:42ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922023-06-0167510.20945/2359-3997000000614Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trialsRodrigo Ribeiro e Silvahttps://orcid.org/0000-0001-9112-6511Mateus de Miranda Gauzahttps://orcid.org/0000-0003-4133-6208Maria Eduarda Schramm Guissohttps://orcid.org/0000-0002-7067-4372Júlia Opolski Nunes da Silvahttps://orcid.org/0000-0003-0903-7080Suely Keiko Koharahttps://orcid.org/0000-0002-5569-0788ABSTRACT Objective: Insulin Icodec is a novel basal insulin analogue designed for once-weekly administration, therefore might propitiate reduction in the frequency of injections and facilitate treatment adherence. This study aimed to determine the glycemic control and safety profile of Insulin Icodec, compared with Glargine U100 in patients with diabetes mellitus type 2. Materials and methods: We performed a systematic review and meta-analysis of randomized controlled trials (RCT) data comparing Once-Weekly Insulin Icodec and Once-Daily Insulin Glargine U100 in patients with type 2 diabetes mellitus. PubMed, Embase, and Cochrane databases were searched for trials published up to May 14, 2022. Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Results: Three studies were included comprising 453 patients, 230 (50.77%) using Once-Weekly Insulin Icodec and 223 (49.22%) using Once-Daily Insulin Glargine U100. In the pooled data, Glycated Hemoglobin (MD -0.20% CI -0.33 to -0.07%; P=0.002) change from baseline demonstrated a significantly higher reduction in the Icodec group. Time with Glucose in Range (MD 6.60% CI 3.63 to 9.57%; P < 0.0001) and Insulin Dose Difference (MD 0.97UI CI 0.76 to 1.18UI; P < 0.0001) were higher in the Icodec group. There was no significant difference in fasting plasma glucose, body weight change, hypoglycemia or any adverse event evaluated. Conclusions: Once-Weekly Insulin Icodec was associated with a small reduction in Glycated Hemoglobin, as well as higher Time with Glucose in Range, with similar hypoglycemic adverse events, when compared with Once-Daily Insulin Glargine U100.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000500200&lng=en&tlng=enType 2 diabetes mellitusinsulininsulin long-actinginsulin glargineinsulin icodecglycemic controlglycated hemoglobin A |
| spellingShingle | Rodrigo Ribeiro e Silva Mateus de Miranda Gauza Maria Eduarda Schramm Guisso Júlia Opolski Nunes da Silva Suely Keiko Kohara Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials Archives of Endocrinology and Metabolism Type 2 diabetes mellitus insulin insulin long-acting insulin glargine insulin icodec glycemic control glycated hemoglobin A |
| title | Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials |
| title_full | Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials |
| title_fullStr | Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials |
| title_full_unstemmed | Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials |
| title_short | Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials |
| title_sort | once weekly insulin icodec vs once daily insulin glargine u100 for type 2 diabetes a systematic review and meta analysis of phase 2 randomized controlled trials |
| topic | Type 2 diabetes mellitus insulin insulin long-acting insulin glargine insulin icodec glycemic control glycated hemoglobin A |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000500200&lng=en&tlng=en |
| work_keys_str_mv | AT rodrigoribeiroesilva onceweeklyinsulinicodecvsoncedailyinsulinglargineu100fortype2diabetesasystematicreviewandmetaanalysisofphase2randomizedcontrolledtrials AT mateusdemirandagauza onceweeklyinsulinicodecvsoncedailyinsulinglargineu100fortype2diabetesasystematicreviewandmetaanalysisofphase2randomizedcontrolledtrials AT mariaeduardaschrammguisso onceweeklyinsulinicodecvsoncedailyinsulinglargineu100fortype2diabetesasystematicreviewandmetaanalysisofphase2randomizedcontrolledtrials AT juliaopolskinunesdasilva onceweeklyinsulinicodecvsoncedailyinsulinglargineu100fortype2diabetesasystematicreviewandmetaanalysisofphase2randomizedcontrolledtrials AT suelykeikokohara onceweeklyinsulinicodecvsoncedailyinsulinglargineu100fortype2diabetesasystematicreviewandmetaanalysisofphase2randomizedcontrolledtrials |